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Abstract
Background: Thyroid disorders are an actual problem of contemporary medicine.  Hypothyroidism represents the insufficiency of thyroid to secrete 
thyroid hormones in necessary quantities for human body.  Primary hypothyroidism is the most common endocrine disease.  Although the diagnosis 
and treatment of hypothyroidism is often considered simple, there are large numbers of people with this condition who are suboptimally treated.  We 
are very concerned that some patients with and without thyroid disease are being inappropriately diagnosed and managed, using levothyroxine  and 
other thyroid hormones, in ways which compromise patient safety.  Subclinical hypothyroidism has multiple etiologies and manifestations.  Appropriate 
treatment requires an accurate diagnosis and is influenced by coexisting medical conditions.  Clinical symptoms of hypothyroidism are nonspecific and 
may be subtle, especially in older persons.  Diagnosis and treatment of hypothyroidism is often considered simple and is mostly carried out in a primary 
care setting.  The dangers of statin use in hypothyroid patients have been illustrated and the necessity for appropriate biochemical monitoring has been 
emphasized.  Statin therapy is safe and effective when patients are appropriately diagnosed, educated, and followed up.  Statins can be cautiously reinitiated 
once a euthyroid state has been established in patients who developed statin-induced myopathy while hypothyroid.
Conclusions: Despite the fact that nowadays problems persist in the management of subclinical hypothyroidism, administration of statins in secondary 
dyslipidemia will prevent cardiovascular diseases especially atherosclerosis thus enhancing the quality of life of patients with hypothyroidism.
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Introduction
Hypothyroidism is the complex syndrome, caused by the 
lack of action of thyroid hormones of different metabolisms, 
devices and systems. Hypothyroidism is one of the most com-
mon thyroid disorders, predominantly in females. According 
to world literature data from 3 to 5% of the population suffer 
from hypothyroidism [3,4]. 
According to some epidemiological studies, the prevalence 
of subclinical hypothyroidism reaches 10-12%. Subclinical 
hypothyroidism, in most cases, does not have clinical manifes-
tations, which would allow it to be suspected. Very often, hy-
pothyroidism occurs being  “disguised” along with numerous 
somatic diseases, gynecological and other endocrine diseases. 
Under many prospective studies, subclinical hypothyroidism 
has quite serious consequences [5.13].
A study conducted on a group of patients in Rotterdam 
(with subclinical hypothyroidism) revealed that the risk 
of atherosclerosis was 1.7 times greater, and that of acute 
myocardial infarction 2.3 times higher than in the general 
population [4 ]. 
With the emergence of highly sensitive methods for 
determining the hormones, subclinical thyroid dysfunction 
concept was formed. The term “subclinical” means that the 
level of thyroid stimulating hormone (TSH) is increased, while 
all the other thyroid functional parameters remain within the 
normal limits. The absence of clear symptoms of subclinical 
hypothyroidism arose the question whether subclinical hy-
pothyroidism is a pathology or a laboratory phenomenon, 
that does not require hormone therapy and normalization 
of TSH. Subclinical hypothyroidism is the subject of several 
studies, which analysis showed that in subclinical hypothyroi-
dism changes in various organs and systems occur, and thyroid 
hormone replacement therapy improves patient’s well-being 
and normalizes many functional parameters [2].
Subclinical hypothyroidism frequency in the general 
population ranges from 1.3 up to 17.5%, depending on age 
and sex. Subclinical hypothyroidism prevalence is higher in 
women than in men and increases with age, reaching the peak 
of 21% of women and 16% men after 74 years. According to 
Framingham study, conducted for 10 years by monitoring 
elderly patients, showed that in studied 2139 patients over 60 
years , subclinical hypothyroidism was detected in 126 patients 
(5.9 % ) and among women almost 2 times more frequently 
[7 ]. Whickham study showed the risk of developing clinical 
hypothyroidism: 4.3% per year, if they show increased serum 
TSH and thyroid antibodies are present from the start, only 
2.6% per year if serum TSH is increased, 2.1 % per year if only 
thyroid antibodies are present, and after 20 years the three 
examined groups have developed hypothyroidism in 55%, 33 
%, 27 % and 4% of those without TSH increased serum and 
thyroid antibodies. The likelihood of developing hypothyro-
idism increases with TSH serum rise [24]. 
In Colorado population studies, which included 25862 
people aged 18-91 years, manifested hypothyroid frequency 
increase and subclinical hypothyroidism with age were also 
observed. As a result of long-term monitoring of patients with 
subclinical hypothyroidism during 4-8 years, it was proved, 
that subclinical hypothyroidism in 20-50% passes into mani-
fested hypothyroidism. In the presence of thyroid antibodies 
in patients aged over 65, the risk of developing manifested 
hypothyroidism in the next four years is 80% [5].
In subclinical hypothyroidism and in the presence of 
thyroid antibodies the risk of developing hypothyroidism 
manifested in the general population is 5% per year. In 
epidemiological studies subclinical hypothyroidism is more 
common, but in clinical practice is less diagnosed [13].
The etiology of subclinical hypothyroidism is the same as 
in manifested hypothyroidism. Subclinical hypothyroidism is 
most often caused by autoimmune thyroiditis. Other proces-
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ses, underlying subclinical hypothyroidism development are 
destroying thyroid tissue with a reduction in its functional 
activity, impaired thyroid hormone synthesis in endemic, 
sporadic goiter in toxic effects on the thyroid gland.
The modern laboratory diagnosis of subclinical hypothy-
roidism is based on TSH and FT4 level determination. The 
manifested hypothyroidism is characterized through TSH 
increased level and FT4 low level and in subclinical hypothy-
roidism TSH level is increased and FT4 levels within the norm. 
Hormonal changes characteristic for primary hypothyroidism 
are based on the principle of negative feedback between the 
thyroid gland and the pituitary gland, in accordance with the 
reduction in T4 and T3 leading to increased synthesis of TSH.
The priority testing in diagnosis of primary hypothyroi-
dism is assessing TSH.
It should be noted that subclinical hypothyroidism may 
be transient and it is not always possible to avoid technical 
errors in determining hormones. Therefore, for subclinical 
hypothyroidism diagnosis TSH levels and FT4 should be re-
peated within 3-6 months and if TSH increase is confirmed, 
a decision on replacement therapy will be taken.
The data from the specialty literature show that in patients 
with hypothyroidism various disorders of the cardiovascular 
system can develop, first of all the changes generated by 
the increase of cholesterol, of lipids with a low density and 
triglycerides. Protein metabolism is disturbed by the basic 
structures impairment of myocardial contractile proteins, as 
well as, by changes in the cardiovascular system and contribute 
to the composition of the fluid from the pericardial effusion, 
and fibrinolysis system disorders [2, 4]. 
In patients with subclinical hypothyroidism endothelial 
dysfunction is determined (early marker of atherosclerosis), 
which can be reversible on the background therapy with 
levothyroxine. Subclinical hypothyroidism is 2-3 times more 
often detected in patients with hypercholesterolemia. In in-
dividuals with subclinical hypothyroidism elevated levels of 
triglycerides, low density lipoproteins (LDL), apolipoprotein 
B and lipoprotein A are identified. The atherogenic changes of 
lipid profile diminish on levothyroxine replacement therapy 
background [6.14].
In patients with subclinical hypothyroidism, as in manifes-
ted hypothyroidism the myocardial hypertrophy, hypertrophy 
of interventricular septum, the maximum increase rate of atria 
blood flow, are determined reducing the average value of the 
acceleration of blood flow in the aorta, to extend the relaxation 
isovolumic period, inferior variation of systolic index.
Thyroid hormones exert different effects on the cardi-
ovascular system and its hemodynamics. Cardiac activity 
indicators such as heart rate, cardiac output, blood flow, 
blood pressure, total peripheral vascular resistance, cardiac 
contractile function, are directly linked to thyroid function 
status. Changes of cardiovascular system in insufficiency of 
thyroid hormones are: coronary atherosclerosis, ischemic 
heart disease, arrhythmias and management disturbances, 
arterial hypertension. 
According to the results of the Rotterdam study (a. 2000), 
subclinical hypothyroidism was detected in 10.8% of women 
aged 69 ± 7.5 years, which often have been associated with 
signs of aortic atherosclerosis and myocardial infarction. 
In subclinical hypothyroidism the level of LDL and total 
cholesterol in contrast with the total cholesterol is positively 
correlated with the level of TSH and negatively with FT4 level. 
Meanwhile, the level of high-density lipoprotein (HDL) decre-
ases, and the ratio between total cholesterol / HDL increases. 
However, data on subclinical hypothyroidism lipid disorders 
are contradictory. In some studies there were neither increased 
cholesterol levels nor lipid metabolism dynamic parameters 
during treatment with levothyroxine [4].
In a study conducted in 2004, researchers examined and 
pursued the association between subclinical hypothyroidism 
and cardiovascular disease in a group of 212 men and wo-
men aged between 20 and 69 years without a known thyroid 
pathology, untreated with drugs that interfere with thyroid 
function or with TSH analysis. There have studied the cli-
nical signs of cardiovascular disease based on the indices of 
lipid metabolism, atherosclerotic risk markers, C-reactive 
protein and TSH. It was found high incidence of subclinical 
hypothyroidism 19.7% in the investigated group. Subclinical 
hypothyroid was associated with higher concentrations of 
triglycerides and C-reactive protein. Cardiovascular disease 
was more common in men under the age of 50 years with 
subclinical hypothyroidism compared to the euthyroid ones. 
The probability report for cardiovascular disease was 3.4 (con-
fidence interval (1.6 to 6.8) compared to euthyroid men of the 
same age. In the NHANES III study, where people Caucasian, 
African-American and Hispanic races were investigated the 
prevalence of hypothyroidism was 5.1%, 1.7% and 4.1% and 
the category the most susceptible included the woman in 
the “post-partum” and also subjects with a family history of 
autoimmune thyroid disorders [25 26]. 
Subclinical hypothyroidism in pregnant women has certa-
in features. During pregnancy, a number of factors that have 
an impact on its functional activity are seen. These factors 
include: the excess synthesis of human chorionic gonadotro-
pin (hCG), estrogens, which induce an increased synthesis of 
transport proteins, which cause a decrease in the free fraction 
of the thyroid hormones, the increase of renal iodine clearance 
and the change of the metabolism of thyroid hormones in cor-
relation with active functioning of the fetus placental complex. 
These factors contribute to the increased synthesis of thyroid 
hormones during pregnancy by 30-50%. In first trimester of 
pregnancy placenta actively produces hCG. Increased hCG 
level leads to stimulation of the thyroid gland, increased levels 
of FT4, which after negative feedback mechanism reduces 
the level of TSH. In the second trimester of pregnancy the 
production of hCG reduces and TSH returns back to normal. 
So now, thanks to the variety of factors that act on the thyroid 
gland during pregnancy, altering thyroid function, in different 
trimesters of pregnancy, has its own characteristics. In the first 
trimester, due to overproduction of hCG, gestational transient 
thyrotoxicosis can develop, which should be distinguished 
from true thyrotoxicosis. The reduction of FT4 in the first 
trimester instead of the expected growth should alert the cli-
nician for an increased risk of hypothyroidism. The presence 
63
REvIEw ARTIClES
64
Curierul medical, December 2015, Vol. 58, No 6
of both subclinical and manifested hypothyroidism can have 
irreversible consequences for the fetus development, primarily 
for the central nervous system. It is known that during the 
first 16 weeks of pregnancy, the thyroid gland of the fetus is in 
the process of formation and the fetal development is realized 
only formed under the action of thyroid hormones of the 
mother. If during pregnancy the lack of thyroid hormone is 
not adjusted, in women with hypothyroidism, the child may 
have malformations and decreased intelligence. Numerous 
studies have shown that children born from mothers who 
have not been treated for subclinical hypothyroidism have a 
low coefficient of intellect, of survival, Apgar score is worse 
compared with the children whose mothers had received 
appropriate dose of levothyroxine. 
It is necessary to conduct immediately a screening for 
hypothyroidism, including the subclinical stage for all preg-
nant or planning a pregnancy women for a thyroid hormone 
replacement therapy.
In hypothyroidism associated with pregnancy, the deter-
mination of serum TSH in pregnant women should be done 
at the first visit, which is one of the most useful investigati-
ons, giving the high specificity of TSH, which can diagnose 
subclinical forms. The level of TSH> 4.0 mU / L, requires the 
determination of fT4, which also has a high sensitivity. The 
dosage of antithyroperoxydase - ATPO antibody is indicated, 
to exclude an autoimmune process because ATPO positive 
women with hypothyroidism have a higher risk of miscarriage 
or premature birth and to develop a portpartum thyroiditis. 
For hypothyroid screening dosage of T3 and  T4 free levels 
will be done. Monitoring of pregnancies with hypothyroidism 
should be complex - clinical, biochemical and ultrasound, 
but thyroid parameters monitoring will be done dynamically. 
Thyroid insufficiency during pregnancy requires maintainan-
ce of TSH in the first trimester is less than 2.5 mIU / l, while 
the second and third trimesters is less than 3 mIU / l. The 
discovery of hypothyroidism during pregnancy requires the 
administration of an early treatment, since starting the follow 
up of a pregnant woman, ideally from 4-8 weeks of gestation to 
prevent maternal-fetal complications. The dose of the thyroid 
hormones should be adjusted to maintain TSH serum under 
2.5 M / l, which requires control of TSH repeatedly at every 
4-8 weeks of gestation. In pregnant women with hypothyroi-
dism pre-existing to pregnancy it’s recommended to increase 
the dose of L-thyroxine on an average by 50% compared with 
preconception dose. The collaboration between obstetrician 
and endocrinologist is particularly important for preventing 
complications associated with maternal-fetal hypothyroidism 
in pregnancy [1,13]. 
 In women with subclinical hypothyroidism vaginal ble-
eding, infertility, failure during in vitro fertilization, preterm 
delivery, placental abruption, high blood pressure are more 
common, cesarean need arises. Pregnancy in hypothyroidism 
is accompanied by an increased incidence of anemia, pree-
clampsia, eclampsia and uteroplacental apoplexy, there is a 
tendency to swelling and weight gain due to fluid retention. 
Subclinical hypothyroidism is often transient, which can 
develop as a result of destructive forms of thyroiditis (subacu-
te, induced by amiodarone) and can be determined as options 
of autoimmune thyroiditis (postpartum), especially in women 
with personal or family history of autoimmune thyroiditis. 
Postpartum thyroiditis occurs in 3-6 months after birth and is 
manifested by hypothyroidism or hyperthyroidism. Hyperthy-
roidism lasts 1-3 months, after which most women return to 
normal thyroid function, or may have hypothyroidism. Thy-
roid dysfunction is due to a destructive thyroiditis associated 
with thyroid microsomal autoantibodies. Postpartum thyro-
iditis often tends to recur in subsequent pregnancies, which 
ultimately develop subclinical or manifested hypothyroidism. 
Subclinical hypothyroidism can develop after surgery, 
antithyroid drug administration, potassium perchlorate, 
lithium preparations. TSH research is recommended in 3-6 
months and if it is necessary, the replacement therapy with 
levothyroxine administration and TSH level will be repeated 
after 3 months [10,11,12].
Treatment
Until the mid-twentieth century hypothyroidism treatment 
was performed using animal thyroid extract. The emergence 
of synthetic thyroid hormone treatment has fundamentally 
changed the treatment of thyroid pathology. Levothyroxine 
therapy in hypothyroidism is considered the “gold standard” 
[13], there are several reasons for this statement:
• easy diagnosis of hypothyroidism (in most cases only by 
determining the level of TSH);
• the single vital function of the thyroid gland is to produce 
thyroid hormones;
• the circadian rhythm of secretion of thyroid hormone 
is almost absent and, therefore, the daily intake of levo-
thyroxine, in the same dose is sufficient;
• high bioavailability for peroral administration of levo-
thyroxine;
• breaking time of levothyroxine in plasma (approximately 
7 days);
• availability of the exact test (TSH level), which fully 
reflects the quality of compensation of hypothyroidism;
• relatively low price of levothyroxine;
• Patients that administer sufficient doses of levothyro-
xine are recommended to determine TSH levels once 
in 6-12 months.
• The quality of life in patients with hypothyroidism, who 
permanently administer levothyroxine and are com-
pensated, is no different from that of patients without 
hypothyroidism. 
 According to population surveys conducted by K. Peter-
son [8], which lasted for 12 years (1968-1969 up to 1980-1981), 
and that included 1462 middle-aged women, in 29 women 
aged up to 28 years levothyroxine replacement therapy was 
administered with the diagnosis of primary hypothyroidism. 
As a result, it was shown that the duration and the quality of 
life and the risk of major diseases, did not differ in patients 
with hypothyroidism treated with levothyroxine, and in the 
control group (n = 968). The treatment of hypothyroidism, 
regardless of its clinical form, is substituted by administering 
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thyroid hormones. The effectiveness of therapy is judged by 
clinical status, normalization of hormonal status. The treat-
ment lasts a lifetime, and for the hypothyroidism replacement 
therapy levothyroxine is indicated. 
In adults levothyroxine dose of 1.6 mcg / kg of body weight 
per day is indicated. The need for levothyroxine is significantly 
higher in children and can be from 2 micrograms / kg to 5 
mcg / kg per day.
The need for levothyroxine decreases with age. Some 
elderly can manage no more than 1  mcg / kg per day of 
levothyroxine for hypothyroidism compensation. The need 
for levothyroxine increases during pregnancy. Evaluation of 
thyroid function in pregnant women with TSH and free T4 
is recommended every trimester of pregnancy.
The starting dose of the drug is determined individually 
depending on the age, body weight, and the presence of con-
comitant cardiovascular diseases.
Subclinical hypothyroidism treatment is solved indi-
vidually. Taking into consideration the high frequency of 
dyslipidemy and atherosclerosis and increased risk of heart 
attack justifies the prescription of levothyroxine for subclinical 
hypothyroidism. The indications for replacement therapy with 
levothyroxine TSH levels are ≥ 10 IU / L or TSH level between 
5 and 10 mU / l and concomitant dyslipidemia. Typically, the 
starting dose is selected based on the age of the patient and 
the presence of concomitant heart pathology. The aim of re-
placement therapy is to maintain subclinical hypothyroidism 
TSH values in the range of 0.5-2.0 mIU / l [6,13].
TSH level varies slowly after a change in dose of levothy-
roxine. TSH level will be examined sooner than 6-8 weeks 
after changing the dose.
The treatment should be slowly progressive, with a gradual 
dose increase, especially in the elderly ones and in case of 
severe hypothyroidism. It begins with daily doses of 25 mcg 
levothyroxine and gradually rising every 7-14 days, at doses 
of 50, 75, 100, 125 mcg etc. until euthyroid state is achieved. 
For older people, 1 mcg/kg of levothyroxine per day is enough 
for compensation of hypothyroidism.
The treatment of subclinical hypothyroidism in patients 
with concomitant cardiac disease, particularly coronary artery 
disease and cardiac arrhythmias should begin with minimal 
doses of levothyroxine - from 12.5 to 25.0 mcg, by gradually 
increasing the dose with 12.5 to 25.0 mcg every 1-2 months 
to reduce TSH levels to normal levels. Replacement therapy 
is performed under ECG supervision or Holter ECG moni-
toring, avoiding decompensation of cardiac abnormalities or 
arrhythmias. After values normalization it is recommended 
to repeat TSH after 3-6 months [2.14].
In elderly and coronary subjects is recommended the 
concomitant use of β- blockers coronary dilators, calcium 
channel blockers.
The effectiveness of therapy is judged by clinical status, 
normalization of hormonal status and of parameters, indi-
cating the action of thyroid hormone at the level of tissue 
receptor. 
Ideally, levothyroxine is administered on an empty stoma-
ch, 30 minutes before a meal. 
It will be taken into account the possible medicaments 
interactions: thyroid hormones intensify K antivitaminic acti-
ons, which are important in the blood clotting process, reduce 
the permeability of capillaries, promote tissue regeneration, 
enhance the action of tricyclic antidepressants, reduce hypo-
glycaemic action. Their action is reduced by cholestyramine. 
Often, levothyroxine hormone replacement finally nor-
malizes the lipid metabolism, nervous system and psycho-
emotional sphere disorders.
If the hormone replacement therapy does not lead to nor-
malization of plasma lipids, the patients with hypothyroidism 
are indicated a  lipid-lowering therapy [15].
The most perspective drugs for the correction of lipid 
metabolism are in present inhibitors of 3-hydroxy-3-methy-
lglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme 
that catalyzes an early step in the biosynthesis of cholesterol.
The statins along with the lipid-lowering effect have a 
number of pleiotropic effects: anti-inflammatory, antioxidant, 
anti-thrombotic properties. Statins are the most effective 
cholesterol lowering drugs acting selectively on HMG-CoA 
reductase, the key enzyme in cholesterol synthesis; they 
decrease LDL-C by 20-40% triglycerides - by 10-20% and 
increase LDH-C by 5-10% [23].     Statins are the most suc-
cessful cardiovascular drugs that have the ability to prolong 
life and to improve its quality. These data confirm the over-
riding importance and need for hypolipimiant treatment in 
hypothyroidism.
Complication of statin therapy is the myopathy induced by 
these drugs [15,16], which is manifested through spontaneous 
muscle pains, cramps and weakness that are typical clinical 
features, regardless of other factors. The risk of myopathy 
increases by the concomitant use of fibrates, inhibitors of 
hepatic cytochrome P-450, major trauma and surgery. The 
most servere complication is rhabdomyolysis [19] having a 
lethal potential [17,18]. Data from clinical trials show that the 
rate of statin-induced myopathy in the general population is 
0.1% to 0.2%. Knowing this negative effect of statins is very 
important, the risk being possibility of myopathy appearance 
due to hypothyroidism. Hypothyroid myopathy was first of 
all described by Johann Hoffmann in 1887. In patients with 
primary hypothyroidism this syndrome may occur with a 
frequency of 25% - 60%. Hypothyroid myopathy manifests 
with muscle fatigue, myalgia, slowness in movements, mus-
cle stiffness [18]. Sometimes muscle weakness, “rigidity” of 
muscles are accompanied by severe myalgia and a significant 
increase in the serum of creatine phosphokinase (CK). A 
number of publications report the association of myopathy 
with rhabdomyolysis complicated by acute muscle necrosis, 
due to the lack of diagnosis of hypothyroidism in time [17,18].
Although the biochemical mechanism both of myo-
pathy in hypothyroidism and that induced by statins 
remains unclear, but hypothyroidism increases the risk of 
statin-induced myopathy [15,16]. However, some authors 
believe that for the mechanism of myopathy hypothyroid 
are responsible glycogenolysis defects or impairment of 
mitochondrial oxidation [17]. Presumably, these mechanis-
ms are synergistic when statins are prescribed to patients 
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with hypothyroidism. Myopathy is more likely to occur 
after administering high doses of statins to patients with 
acute coronary syndrome who undergo coronary angio-
plasty [21]. Therefore the use of statins in patients with 
hypothyroidism should be carefully indicated. Biochemical 
testing is essential for patients with symptoms that can be 
attributed to myopathy on the background of statin therapy.
ATP III (Adult Panel III) guide of the National Cholesterol 
Education Program 13 and American College of Cardiology 
ACC / AHA 11 recommend that the determination of creatine 
phosphokinase (CK) is determined before initiating statin 
therapy and that will be re-evaluated in comparison with the 
initial if patients report any muscle symptoms. More frequent 
determinations of CK and transaminase are indicated to pa-
tients, that got maximum statin doses and those who receive 
a combination therapy, usually with fibrates [21,22]. Finally, 
statins are not absolutely contraindicated to patients who 
developed myopathy induced by statins [20,22]. Statin therapy 
should be performed with caution, with re-initiation of statins 
therapy in this context, and the patients should always be in-
structed that if muscle pains or cold-like symptoms develop, 
statins should be discontinued immediately and they should 
contact the doctor. 
Conclusions
Hypothyroidism is a well-known cause of secondary dys-
lipidemia and the link with atherosclerosis has been known 
for 125 years. Elevated circulating levels of a very low den-
sity lipoprotein (VLDL) and low density lipoproteins (LDL) 
cholesterol are major lipid abnormalities observed in patients 
with hypothyroidism. 
The reduction in circulating levels of atherogenic lipo-
proteins (VLDL and LDL) is the main goal of treatment with 
statins. In addition, the statins possess pleiotropic properties: 
improve endothelial dysfunction, have anti-inflammatory, 
antioxidant, antiplatelet, antiproliferative effect; stabilize and 
slow the progression of atherosclerotic plaque.
Thus the administration of statins in secondary dyslipi-
demy will help to prevent cardiovascular diseases, especially 
atherosclerosis, which will enhance the quality of life of pati-
ents with hypothyroidism.
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